What Is Adipotide (FTPP / Prohibitin-TP01)? A Research Overview

Adipotide, also called FTPP or Prohibitin-TP01, is an experimental peptidomimetic studied in animal models for its targeting of adipose-tissue vasculature. Bolt Peptide does not offer Adipotide. It is discussed only as an experimental research compound and not for human use.

Quick facts

• Class: targeted pro-apoptotic peptidomimetic (a homing peptide fused to a pro-apoptotic sequence).
• Molecular target: prohibitin (and the associated protein annexin A2) on the endothelium of white-adipose-tissue blood vessels.
• Research focus: adipose-vasculature research — the blood supply that feeds fat depots.
• Status: experimental; studied in rodents and non-human primates; documented toxicity concerns in those studies.

What is Adipotide?

Adipotide is a laboratory-designed peptidomimetic with the sequence CKGGRAKDC–GG–D(KLAKLAK)₂. It is built from two functional halves. The first half is a short “homing” peptide (CKGGRAKDC) that, in animal models, binds to prohibitin on the inner lining of blood vessels that supply white adipose tissue. The second half — the D(KLAKLAK)₂ segment — is a pro-apoptotic sequence that disrupts cell membranes and mitochondria once delivered inside a cell. By chemically tethering a targeting sequence to a cell-killing sequence, researchers designed a single molecule intended to concentrate its activity at adipose-tissue vasculature rather than acting throughout the body.

What does the research show?

Foundational animal studies reported quantitative adipose-tissue, imaging, and renal-marker observations in mouse and non-human-primate models. The authors also documented renal proximal-tubule findings under the tested experimental conditions. These observations are summarized only as part of the non-human scientific record and do not translate into a protocol or claim for humans.

Mechanisms studied in the lab

• Prohibitin targeting: in animal studies, the homing portion binds prohibitin (and annexin A2) displayed on endothelial cells of white-adipose-tissue blood vessels.
• Apoptosis of adipose endothelial cells: once localized, the pro-apoptotic segment is associated with programmed death of those endothelial cells, which in animal models reduced the blood supply to fat depots.

Research status and safety

Adipotide has a limited animal-model evidence base that includes documented toxicity concerns. Bolt Peptide does not sell it. This article is a research-use-only educational reference for qualified researchers; it is not for human or veterinary use.

Related research compounds

If you are researching peptides studied in metabolic and adipose-tissue contexts, browse our full research-peptide catalog. You may also find our overview of AOD-9604 — a different, separately studied fragment-based research peptide — useful as background reading.

FAQ

What is the evidence base for Adipotide? Published evidence is limited to experimental animal models. Bolt Peptide does not offer this compound, and nothing here is a human-use claim.

Why does Adipotide literature discuss kidney markers? A cited non-human-primate study reported renal proximal-tubule observations under its experimental conditions. The finding is presented only as part of the animal-research record.

Does Bolt Peptide sell Adipotide? No. This article is educational only. Review what we do carry in our peptide catalog.

References

1. Kolonin MG, et al. Reversal of obesity by targeted ablation of adipose tissue. Nat Med. 2004.
2. Barnhart KF, et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med. 2011.

For research use only. Adipotide is an experimental compound studied only in animals, with documented toxicity in those studies; not for human or veterinary use, not a supplement. Statements have not been evaluated by the FDA.